Sun Pharma’s premium push cushions US generics pain in Q1, but valuations look full
Sun Pharmaceutical Industries Ltd reported a 10% year-on-year revenue increase to ₹15,183 crore for Q1FY27, driven by strong growth in India formulations and innovative medicines. The company maintained its FY27 guidance despite facing near-term margin pressure from investments and the Organon acquisition, with India formulations growing 16% year-on-year. However, the US generics segment struggled, with revenue declining 9.7% to $427 million due to lower sales of certain products.